Summarized by Masters of Longevity from PR Newswire.
Leqembi Pen coverage previews a regulatory update about a new once-weekly at-home subcutaneous autoinjector option for treating early Alzheimer’s disease, highlighting patient-friendly administration and expected impacts on care delivery.
Key Takeaways
- Japan approved a once-weekly 500 mg subcutaneous autoinjector formulation for early Alzheimer's disease treatment.
- Integrated Phase 3 Clarity AD core data and LTE sub-studies showed similar exposure to IV dosing and supported comparable efficacy expectations.
- Subcutaneous administration had a generally similar safety profile and fewer systemic injection or infusion reactions (1.4%).
